Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charu Aggarwal

Showing results (41-50 of 169) with videos related to

Pageof 17
Sort By:
Cancer Treatment and Research Communications|April 28, 2026
Evaluation of guideline-recommended care in first-line treatment for advanced/metastatic non-small cell lung cancer patients who underwent next-generation sequencing testing: results from a real-world studyMelina E Marmarelis, Adrienne M Gilligan, Tomoko Sugihara, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2019
Prevention and Early Detection for NSCLC: Advances in Thoracic Oncology 2018Haval Balata, Kwun M Fong, Lizza E Hendriks, et al.
Clinical Lung Cancer|June 21, 2025
Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status-A Real-World Analysis in Patients With Advanced NSCLCDavid J Cantor, Halla Nimeiri, Leora Horn, et al.
Annals of Translational Medicine|October 24, 2017
Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancerMelina Marmarelis, Jeffrey C Thompson, Charu Aggarwal, et al.
Frontiers in Oncology|May 8, 2026
Carboplatin plus pemetrexed versus pemetrexed alone in advanced thymoma and thymic carcinoma: a retrospective cohort studyBenjamin A Bleiberg, Lauren Reed-Guy, Roger B Cohen, et al.
Cancer|March 6, 2015
Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508)Nasser H Hanna, Suzanne E Dahlberg, Jill M Kolesar, et al.
JTO Clinical and Research Reports|May 27, 2024
Brief Report: Long-Term Follow-Up of Adjuvant Pembrolizumab After Locally Ablative Therapy for Oligometastatic NSCLCDavid J Cantor, Christiana Davis, Christine Ciunci, et al.
Scientific Reports|January 19, 2023
Sinococuline, a bioactive compound of Cocculus hirsutus has potent anti-dengue activityRahul Shukla, Richa Ahuja, Hemalatha Beesetti, et al.
Clinical Lung Cancer|November 14, 2017
Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non-Small-cell Lung Cancer: Results of a Phase II StudyCharu Aggarwal, Roger B Cohen, Eddy Yu, et al.
Scientific Reports|October 3, 2025
Development of a prognostic multiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first line immunotherapyApurva Singh, Hannah Horng, Leonid Roshkovan, et al.
Pageof 17

Showing results (41-50 of 169) with videos related to

Sort By:
Pageof 17
Cancer Treatment and Research Communications|April 28, 2026
Evaluation of guideline-recommended care in first-line treatment for advanced/metastatic non-small cell lung cancer patients who underwent next-generation sequencing testing: results from a real-world studyMelina E Marmarelis, Adrienne M Gilligan, Tomoko Sugihara, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2019
Prevention and Early Detection for NSCLC: Advances in Thoracic Oncology 2018Haval Balata, Kwun M Fong, Lizza E Hendriks, et al.
Clinical Lung Cancer|June 21, 2025
Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status-A Real-World Analysis in Patients With Advanced NSCLCDavid J Cantor, Halla Nimeiri, Leora Horn, et al.
Annals of Translational Medicine|October 24, 2017
Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancerMelina Marmarelis, Jeffrey C Thompson, Charu Aggarwal, et al.
Frontiers in Oncology|May 8, 2026
Carboplatin plus pemetrexed versus pemetrexed alone in advanced thymoma and thymic carcinoma: a retrospective cohort studyBenjamin A Bleiberg, Lauren Reed-Guy, Roger B Cohen, et al.
Cancer|March 6, 2015
Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508)Nasser H Hanna, Suzanne E Dahlberg, Jill M Kolesar, et al.
JTO Clinical and Research Reports|May 27, 2024
Brief Report: Long-Term Follow-Up of Adjuvant Pembrolizumab After Locally Ablative Therapy for Oligometastatic NSCLCDavid J Cantor, Christiana Davis, Christine Ciunci, et al.
Scientific Reports|January 19, 2023
Sinococuline, a bioactive compound of Cocculus hirsutus has potent anti-dengue activityRahul Shukla, Richa Ahuja, Hemalatha Beesetti, et al.
Clinical Lung Cancer|November 14, 2017
Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non-Small-cell Lung Cancer: Results of a Phase II StudyCharu Aggarwal, Roger B Cohen, Eddy Yu, et al.
Scientific Reports|October 3, 2025
Development of a prognostic multiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first line immunotherapyApurva Singh, Hannah Horng, Leonid Roshkovan, et al.
Pageof 17